Cerenome, Inc. (CNSY) - Total Assets
Based on the latest financial reports, Cerenome, Inc. (CNSY) holds total assets worth $19.92 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Cerenome, Inc. current assets vs equity to assess how much short-term liquidity the company maintains relative to its equity base.
Cerenome, Inc. - Total Assets Trend (2022–2025)
This chart illustrates how Cerenome, Inc.'s total assets have evolved over time, based on quarterly financial data.
Cerenome, Inc. - Asset Composition Analysis
Current Asset Composition (December 2025)
Cerenome, Inc.'s total assets of $19.92 Million consist of 92.9% current assets and 7.1% non-current assets. Also see CNSY stock market capitalisation for the company's overall valuation and market capitalisation.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 26.1% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $333.00K | 2.0% |
| Goodwill | $372.00K | 2.3% |
Asset Composition Trend (2022–2025)
This chart illustrates how Cerenome, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See latest Cerenome, Inc. stock price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cerenome, Inc.'s current assets represent 92.9% of total assets in 2025, an increase from 91.4% in 2022.
- Cash Position: Cash and equivalents constituted 26.1% of total assets in 2025, down from 75.9% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 1.0% in 2022.
- Asset Diversification: The largest asset category is goodwill at 2.3% of total assets.
Cerenome, Inc. Competitors by Total Assets
Key competitors of Cerenome, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Chongqing Zhifei Bio Products
SHE:300122
|
China | CN¥29.09 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Guangzhou Boji Medical and Biotechnological Co Ltd
SHE:300404
|
China | CN¥1.67 Billion |
Cerenome, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.27 | 1.03 | 1.03 |
| Quick Ratio | 2.27 | 1.03 | 1.03 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $10.07 Million | $309.00K | $309.00K |
Cerenome, Inc. - Advanced Valuation Insights
This section examines the relationship between Cerenome, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.21 |
| Latest Market Cap to Assets Ratio | 1.55 |
| Asset Growth Rate (YoY) | 146.1% |
| Total Assets | $16.32 Million |
| Market Capitalization | $25.33 Million USD |
Valuation Analysis
Above Book Valuation: The market values Cerenome, Inc.'s assets above their book value (1.55x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Cerenome, Inc.'s assets grew by 146.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Cerenome, Inc. (2022–2025)
The table below shows the annual total assets of Cerenome, Inc. from 2022 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $16.32 Million | +146.12% |
| 2024-12-31 | $6.63 Million | -41.75% |
| 2023-12-31 | $11.39 Million | -52.29% |
| 2022-12-31 | $23.87 Million | -- |
About Cerenome, Inc.
Cerenome, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cance… Read more